UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000035172
Receipt No. R000040082
Scientific Title The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase II trial
Date of disclosure of the study information 2018/12/08
Last modified on 2018/12/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase II trial
Acronym Pyridoxamine for ASD trial
Scientific Title The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase II trial
Scientific Title:Acronym Pyridoxamine for ASD trial

Condition Autism spectrum disorder
Classification by specialty
Pediatrics Psychiatry
Classification by malignancy Others
Genomic information NO

Narrative objectives1 Exploritively evaluate the efficacy and safety of pyridoxamine for patients with autism spectrum disorder and determine the appropriate target patient population, dosage regimen, and evaluation index
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase II

Primary outcomes Amount of change from excitatory subscale score from baseline of Abnormal Behavior Checklist Japanese Version (ABC-J)
Key secondary outcomes *ABC-J total score, other subscale score change from baseline
*Sensory profile, repeat behavior scale, Hyperacusis Questionnaire, clinical global impression - improvement, sensory investigation and symptom change questionnaire

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation YES
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment Central registration

No. of arms 3
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 Placebo
Interventions/Control_2 Oral doses of low dose pyridoxamine divided into twice a day for 8 weeks
12-19 year;800mg
20 years or older;1200mg
Interventions/Control_3 Oral doses of high dose pyridoxamine divided into twice a day for 8 weeks
12-19 years;1200mg
20 years or older;2000mg

Age-lower limit
12 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patients diagnosed with autism spectrum discrder by DSM-5.
2. Patients aged 12 years or older at the time of acquisition
3. Patients who have consented to participate in clinical trials from principal and substitute in the document (If the age at the time of consent acquisition is under 20 years old, consent of participation in clinical trial is obtaind from the substitute,regardless of ages, if the patient does not have the ability of agreement, written consent is obtaind from the substitute), and the patient who can visit the outpatient clinic with guardian at the designated time, a designated number of times
4. Patients who scored 18 or more excitatory subscale scores of Abnormal Behavior Checklist Japanese Version (ABC-J)
Key exclusion criteria 1.Patients with a history of hypersensitivity to vitamin B6
2.Patients diagnosed with schizophrenia
3.Patient who is diagnosed with bipolar I disorder, bipolar II disorder, depression / major depressive disorder, and undergoing oral treatment for treatment
4. Patients with severe liver disease or liver injury (AST or ALT> 3 times the upper limit of the facility reference value) at screening
5.Patients with severe heart disease
6.Patients with impaired renal function (creatinine value> 2.0 mg / dL) at screening
7.Patients with gastrointestinal disorders, respiratory disorders, hematological disorders, endocrine disorders, immune disorders or other systemic disorders
8.In case of epilepsy complications, patients who had a epileptic seizure during the last 6 months until subject screening
9. At the beginning of study medication administration, patients using either of the following; vitamin B6, typical antipsychotics, anxiolytics, antihistamine drugs,ADHD therapeutic agent, etc.
10.During the trial period, patients using two or more sleep inducer
11.Patients who can not agree that the dosage regimen of the drugs shown below is in principle unchangeable during the trial period. Patients who do not agree to discontinue taking as needed or to take at a fixed dose when using consent at the time of taking medicine; atypical antipsychotics, sleep inducer, antiepileptic drugs, etc
12.Patients with malignant tumor coexisting at the time of subject screening or undergoing surgery for malignant tumor within 5 years before subject screening
13.Patient who wishes to become pregnant during pregnancy or lactation when subject screening
14.Patients participating in other trials or clinical studies at registration
15.Because of self-injurious behavior, suicidal ideation or other symptoms, the investigator or clinical trial doctor consider as high risks such as poor treatment compliance, failure to complete the trial, obstructing participation in the trial, affecting safety, etc.
Target sample size 72

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Shigeo Kure
Organization Tohoku University Hospital
Division name Department of Pediatrics
Zip code
Address 1-1 Seiryo-cho Aoba-ku Sendai-shi Miyagi-ken Japan
TEL 022-717-7287

Public contact
Name of contact person
1st name
Middle name
Last name Takuto Hanai
Organization C-55 Clinical trial coordinating office
Division name Clinical Research Innovation and Education Center
Zip code
Address 1-1 Seiryo-cho Aoba-ku Sendai-shi Miyagi-ken Japan
TEL 022-717-7136
Homepage URL

Institute Department of Pediatrics,Tohoku University Hospital

Funding Source
Organization Japan Agency for Medical Research and Development
Category of Funding Organization Government offices of other countries
Nationality of Funding Organization Japan

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2

Institutions 東北大学病院(宮城県)、自治医科大学附属病院(栃木県)、国立成育医療研究センター(東京都)、大阪市立総合医療センター(大阪府)、神戸大学医学部付属病院(兵庫県)、宮城県立こども病院(宮城県)、弘前大学病院精神科(青森県)、山形大学医学部付属病院(山形市)、国立精神・神経医療研究センター(東京都)

Other administrative information
Date of disclosure of the study information
2018 Year 12 Month 08 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 07 Month 31 Day
Date of IRB
Anticipated trial start date
2018 Year 08 Month 13 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
2020 Year 03 Month 31 Day

Other related information

Management information
Registered date
2018 Year 12 Month 07 Day
Last modified on
2018 Year 12 Month 10 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.